UA78277C2 - Orally dispersible pharmaceutical piribedil composition - Google Patents

Orally dispersible pharmaceutical piribedil composition Download PDF

Info

Publication number: UA78277C2
Authority: UA; Ukraine
Prior art keywords: pyribedil; pharmaceutical composition; pharmaceutically acceptable; differs; composition according
Prior art date: 2002-01-21

Application number

UA20040806962A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-21

Filing date

2003-01-21

Publication date

2007-03-15

2003-01-21 Application filed by Servier Lab filed Critical Servier Lab

2007-03-15 Publication of UA78277C2 publication Critical patent/UA78277C2/uk

Links

239000000203 mixture Substances 0.000 title claims abstract description 10
OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 title abstract description 6
229960004310 piribedil Drugs 0.000 title abstract description 6
239000008187 granular material Substances 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 10
239000007787 solid Substances 0.000 claims abstract description 10
229920002472 Starch Polymers 0.000 claims abstract description 8
239000008107 starch Substances 0.000 claims abstract description 8
235000019698 starch Nutrition 0.000 claims abstract description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 7
239000008101 lactose Substances 0.000 claims abstract description 7
210000000214 mouth Anatomy 0.000 claims description 18
239000008194 pharmaceutical composition Substances 0.000 claims description 17
208000018737 Parkinson disease Diseases 0.000 claims description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
238000011282 treatment Methods 0.000 claims description 5
238000007906 compression Methods 0.000 claims description 4
230000006835 compression Effects 0.000 claims description 4
230000001154 acute effect Effects 0.000 claims description 3
239000000314 lubricant Substances 0.000 claims description 3
238000011866 long-term treatment Methods 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
239000002552 dosage form Substances 0.000 description 11
239000000945 filler Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
239000007884 disintegrant Substances 0.000 description 4
239000004480 active ingredient Substances 0.000 description 3
200000000007 Arterial disease Diseases 0.000 description 2
206010039424 Salivary hypersecretion Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000010579 first pass effect Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
208000026451 salivation Diseases 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000005303 weighing Methods 0.000 description 2
206010001541 Akinesia Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
206010022562 Intermittent claudication Diseases 0.000 description 1
101100049053 Mus musculus Vash1 gene Proteins 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000021156 intermittent vascular claudication Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Psychology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

UA20040806962A 2002-01-21 2003-01-21 Orally dispersible pharmaceutical piribedil composition UA78277C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0200671A FR2834894B1 (fr)	2002-01-21	2002-01-21	Composition pharmaceutique orodispersible de piribedil
PCT/FR2003/000179 WO2003061661A1 (fr)	2002-01-21	2003-01-21	Composition pharmaceutic orodispersible de piribedil

Publications (1)

Publication Number	Publication Date
UA78277C2 true UA78277C2 (en)	2007-03-15

Family

ID=27589523

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040806962A UA78277C2 (en)	2002-01-21	2003-01-21	Orally dispersible pharmaceutical piribedil composition

Country Status (26)

Country	Link
US (1)	US20050085485A1 (pl)
EP (1)	EP1467737B1 (pl)
JP (1)	JP4500051B2 (pl)
KR (1)	KR100588223B1 (pl)
CN (1)	CN100352440C (pl)
AR (1)	AR038194A1 (pl)
AT (1)	ATE327758T1 (pl)
AU (1)	AU2003214326B2 (pl)
BR (1)	BR0306869A (pl)
CA (1)	CA2473152C (pl)
CY (1)	CY1105414T1 (pl)
DE (1)	DE60305642T2 (pl)
DK (1)	DK1467737T3 (pl)
EA (1)	EA007286B1 (pl)
ES (1)	ES2263959T3 (pl)
FR (1)	FR2834894B1 (pl)
GE (1)	GEP20063819B (pl)
MA (1)	MA27098A1 (pl)
MX (1)	MXPA04007035A (pl)
NO (1)	NO20043474L (pl)
NZ (1)	NZ533820A (pl)
PL (1)	PL204939B1 (pl)
PT (1)	PT1467737E (pl)
UA (1)	UA78277C2 (pl)
WO (1)	WO2003061661A1 (pl)
ZA (1)	ZA200405008B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9597278B2 (en)	2008-11-13	2017-03-21	David A. Hamlin	Compositions and methods for alleviating hyposalivation and for providing oral comfort
US9884082B2 (en)	2008-11-13	2018-02-06	David A. Hamlin	Compositions and methods for alleviating hyposalivation and for providing oral comfort

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE575343A (pl) *	1955-09-09
FR2355502A1 (fr) *	1976-06-23	1978-01-20	Roussel Uclaf	Application a titre de medicaments d'un derive de la piperazine et de ses sels
AT376147B (de) *	1980-12-15	1984-10-10	Gergely Gerhard	Verfahren und vorrichtung zum granulieren eines pulvergemisches
DE3505433A1 (de) *	1985-02-16	1986-08-21	Basf Ag, 6700 Ludwigshafen	Direkttablettierhilfsmittel
DE3506276C1 (de) *	1985-02-22	1986-04-24	Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring	Direkttablettiermittel
JP3253127B2 (ja) *	1991-06-07	2002-02-04	帝國製薬株式会社	生理活性ポリペプチド含有製剤
FR2710265B1 (fr) *	1993-09-22	1995-10-20	Adir	Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs.
NZ278678A (en) *	1994-01-31	1998-03-25	Yamanouchi Pharma Co Ltd	Compressed moulded tablet with quick disintegration/dissolution in the mouth, mixture of low and high moldable saccharides as carriers
GB9517062D0 (en) *	1995-08-18	1995-10-25	Scherer Ltd R P	Pharmaceutical compositions
GB9700878D0 (en) *	1997-01-17	1997-03-05	Scherer Ltd R P	Dosage forms and method for ameliorating male erectile dysfunction
US6024981A (en) *	1997-04-16	2000-02-15	Cima Labs Inc.	Rapidly dissolving robust dosage form
AU730020B2 (en) *	1997-05-09	2001-02-22	Feronpatent Limited	Stabilisation of interferons in aqueous solution for manufacture of sublingually administered tablets
JP2983973B1 (ja) *	1998-10-13	1999-11-29	大正薬品工業株式会社	口腔内速崩壊性固形製剤
JP2000273039A (ja) *	1999-01-20	2000-10-03	Taisho Pharmaceut Co Ltd	口腔内崩壊性組成物
JP2001058944A (ja) *	1999-06-18	2001-03-06	Takeda Chem Ind Ltd	速崩壊性固形製剤
AU2001273496A1 (en) *	2000-07-24	2002-02-05	Boehringer Ingelheim Pharmaceuticals Inc.	Apparatus and method for predicting the suitability of a substance for dry granulation by roller compaction using small sample sizes
DE60036205T2 (de) *	2000-07-27	2008-05-21	Roquette Frères	Granulat bestehend aus Stärke und Laktose
UA80393C2 (uk) *	2000-12-07	2007-09-25	Алтана Фарма Аг	Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US7118765B2 (en) *	2001-12-17	2006-10-10	Spi Pharma, Inc.	Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
FR2834889B1 (fr) *	2002-01-18	2004-04-02	Roquette Freres	Forme pharmaceutique solide orodispersible

2002
- 2002-01-21 FR FR0200671A patent/FR2834894B1/fr not_active Expired - Fee Related
2003
- 2003-01-21 PL PL370168A patent/PL204939B1/pl not_active IP Right Cessation
- 2003-01-21 NZ NZ533820A patent/NZ533820A/en not_active IP Right Cessation
- 2003-01-21 CA CA2473152A patent/CA2473152C/fr not_active Expired - Fee Related
- 2003-01-21 WO PCT/FR2003/000179 patent/WO2003061661A1/fr not_active Ceased
- 2003-01-21 UA UA20040806962A patent/UA78277C2/uk unknown
- 2003-01-21 MX MXPA04007035A patent/MXPA04007035A/es active IP Right Grant
- 2003-01-21 US US10/502,078 patent/US20050085485A1/en not_active Abandoned
- 2003-01-21 PT PT03709892T patent/PT1467737E/pt unknown
- 2003-01-21 EP EP03709892A patent/EP1467737B1/fr not_active Expired - Lifetime
- 2003-01-21 AU AU2003214326A patent/AU2003214326B2/en not_active Ceased
- 2003-01-21 CN CNB038025256A patent/CN100352440C/zh not_active Expired - Fee Related
- 2003-01-21 DK DK03709892T patent/DK1467737T3/da active
- 2003-01-21 BR BR0306869-2A patent/BR0306869A/pt not_active IP Right Cessation
- 2003-01-21 JP JP2003561605A patent/JP4500051B2/ja not_active Expired - Fee Related
- 2003-01-21 DE DE60305642T patent/DE60305642T2/de not_active Expired - Lifetime
- 2003-01-21 ES ES03709892T patent/ES2263959T3/es not_active Expired - Lifetime
- 2003-01-21 GE GE5626A patent/GEP20063819B/en unknown
- 2003-01-21 KR KR1020047011236A patent/KR100588223B1/ko not_active Expired - Fee Related
- 2003-01-21 AT AT03709892T patent/ATE327758T1/de active
- 2003-01-21 AR ARP030100162A patent/AR038194A1/es not_active Application Discontinuation
- 2003-01-21 EA EA200400885A patent/EA007286B1/ru not_active IP Right Cessation
2004
- 2004-06-24 ZA ZA2004/05008A patent/ZA200405008B/en unknown
- 2004-07-06 MA MA27766A patent/MA27098A1/fr unknown
- 2004-08-20 NO NO20043474A patent/NO20043474L/no not_active Application Discontinuation
2006
- 2006-06-30 CY CY20061100899T patent/CY1105414T1/el unknown

Also Published As

Publication number	Publication date
HK1081110A1 (zh)	2006-05-12
ATE327758T1 (de)	2006-06-15
MXPA04007035A (es)	2004-10-11
PL204939B1 (pl)	2010-02-26
KR20040075098A (ko)	2004-08-26
CN100352440C (zh)	2007-12-05
PT1467737E (pt)	2006-08-31
ES2263959T3 (es)	2006-12-16
CY1105414T1 (el)	2010-04-28
KR100588223B1 (ko)	2006-06-12
DE60305642T2 (de)	2007-05-16
BR0306869A (pt)	2004-11-03
WO2003061661A1 (fr)	2003-07-31
NZ533820A (en)	2005-08-26
JP2005529068A (ja)	2005-09-29
EA007286B1 (ru)	2006-08-25
DE60305642D1 (de)	2006-07-06
PL370168A1 (pl)	2005-05-16
EA200400885A1 (ru)	2004-12-30
EP1467737A1 (fr)	2004-10-20
AR038194A1 (es)	2005-01-05
CA2473152C (fr)	2010-08-31
US20050085485A1 (en)	2005-04-21
FR2834894A1 (fr)	2003-07-25
GEP20063819B (en)	2006-05-10
CN1688313A (zh)	2005-10-26
AU2003214326B2 (en)	2007-08-02
ZA200405008B (en)	2005-08-31
FR2834894B1 (fr)	2004-02-27
NO20043474L (no)	2004-08-20
MA27098A1 (fr)	2004-12-20
CA2473152A1 (fr)	2003-07-31
JP4500051B2 (ja)	2010-07-14
DK1467737T3 (da)	2006-09-18
EP1467737B1 (fr)	2006-05-31

Publication	Publication Date	Title
JP4335011B2 (ja)	2009-09-30	アゴメラチンの口腔分散性医薬組成物
US20040265375A1 (en)	2004-12-30	Orally disintegrating tablets
JP2008285434A (ja)	2008-11-27	口腔内速崩壊錠
JP4500052B2 (ja)	2010-07-14	イバブラジンの口腔分散性医薬組成物
UA78279C2 (en)	2007-03-15	Orally dispersible pharmaceutical perindopril composition
CN100544709C (zh)	2009-09-30	抗血栓形成的化合物的可在口中分散的药物组合物
KR20070119654A (ko)	2007-12-20	의약용 조성물
KR100588223B1 (ko)	2006-06-12	경구분산가능한 약제학적 피리베딜 조성물
HK1081110B (en)	2008-05-23	Orally dispersible pharmaceutical piribedil composition
HK1094152B (en)	2010-03-12	Orodispersible pharmaceutical composition of an antithrombotic compound